Test your knowledge of pharma market access & payers in Europe

How well do you know the market access systems of France, Germany, Italy, Spain and the UK? These 5 single-choice questions cover out-of-pocket spending in the EU27, payer archetypes in France, confidential price arrangements, Spain's Valtermed registry and the French ASMR rating. Developed by Dr Nick Proctor and Megan O'Brien, faculty members of Understanding Pharma Market Access & Payers in Europe.  
 

1) What’s the average EU27 out of pocket spend on prescription drugs?

 

  1. About 10%
  2. About 20%
  3. About 30%

C. About 30%

Source: OECD Health Statistics 2022; Eurostat Database.


 

2) How well do you know payer archetypes? Which of the following traditional payer archetypes are present in France?

 

  1. Budget optimisation
  2. Comparative clinical effectiveness
  3. Cost effectiveness
  4. All of the above

D. All of the above

France uses all three archetypes. Want the full framework for grouping payers across European markets? Download the free ebooklet: Slide Snapshot: Payer Archetypes in Europe
 


 

3) Confidential price arrangements are available in which countries?

 

  1. France
  2. Germany
  3. United Kingdom
  4. All of the above

D. All of the above

Confidential price arrangements, such as managed-entry agreements and discount/rebate schemes are used across most major European markets (and beyond) as a cost-containment mechanism by health systems, but also as a method of protecting net price by manufacturers.


 

4) In Spain, what is Valtermed?

 

  1. A robot for treating patients
  2. A registry-based managed access programme for high cost drugs
  3. A hospital drama series

B. A registry-based managed access programme for high cost drugs

Valtermed is the Spanish Ministry of Health's national outcomes registry, used jointly with the regions to track real-world results of high-cost medicines (particularly oncology and other specialist drugs) and tie continued funding to the evidence collected.


 

5) What does ASMR usually stand for in market access?

 

  1. The measure of added medical benefit (amélioration du service médical rendu) in France
  2. Autonomous Sensory Meridian Response
  3. Adding Sales Means Rebates

A. The measure of added medical benefit (amélioration du service médical rendu) in France

ASMR stands for "Amélioration du Service Médical Rendu," the rating given by France's Haute Autorité de Santé (HAS) Transparency Committee to express how much additional clinical benefit a new medicine provides compared with existing treatments, which in turn shapes the price it can obtain.

Continue your learning from Nick and Megan

If you’d like to learn more from Nick and Megan, CELforPharma also offers a 1-day, hands-on course where you'll:

  • Demystify market access concepts and payer decision-making
  • Understand payer archetypes and how they differ across countries
  • Gain clarity on evidence expectations and access pathways in major EU markets
  • Learn how to embed market access into a cross-functional strategic process
Understanding Pharma Market Access & Payers in Europe
With Dr Nick Proctor & Megan O'Brien
Dr. Nick Proctor
Megan O'Brien

Don’t miss the latest insights from our expert faculty

Subscribe to our newsletter to:

  • Stay on top of the latest expert insights
  • Receive invitations to upcoming educational webinars
  • Get updates on our courses and training programmes